NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
about
The search for novel analgesics: targets and mechanismsPain as a channelopathyEffects of neurokinin-1 receptor agonism and antagonism in the rostral ventromedial medulla of rats with acute or persistent inflammatory nociceptionThe pharmacology of neurokinin receptors in addiction: prospects for therapyThe perception and endogenous modulation of painGut-brain peptides in corticostriatal-limbic circuitry and alcohol use disordersRedox-Dependent Modulation of T-Type Ca(2+) Channels in Sensory Neurons Contributes to Acute Anti-Nociceptive Effect of Substance PPotential therapeutic targets for neurokinin-1 receptor antagonistsIdentification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigreesMorphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effectsAnimal models of chronic pain: Advances and challenges for clinical translation.A role for fMRI in optimizing CNS drug development.Validation, reproducibility and safety of trans dermal electrical stimulation in chronic pain patients and healthy volunteers.In search of analgesia: emerging roles of GPCRs in pain.Substance P, opioid, and catecholamine systems in the mouse central nervous system (CNS).Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial.Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders.Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Involvement of substance P and the NK-1 receptor in human pathology.Review article: current and emerging therapies for functional dyspepsia.Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs.Role of tachykinin 1 and 4 gene-derived neuropeptides and the neurokinin 1 receptor in adjuvant-induced chronic arthritis of the mousePET-scan shows peripherally increased neurokinin 1 receptor availability in chronic tennis elbow: visualizing neurogenic inflammation?Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.Lost but making progress--Where will new analgesic drugs come from?Dorsal horn neurons expressing NK-1 receptors mediate scratching in rats.Perioperative nerve blockade: clues from the bench.Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch.Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.Predictive validity of behavioural animal models for chronic painAn antinociceptive role for substance P in acid-induced chronic muscle pain.Comparison of NK-1 Receptor Antagonist (Maropitant) to Morphine as a Pre-Anaesthetic Agent for Canine OvariohysterectomyCell signaling and the genesis of neuropathic pain.Mechanical Conflict System: A Novel Operant Method for the Assessment of Nociceptive Behavior.Molecular and cellular mechanisms that initiate pain and itch.Negative reinforcement reveals non-evoked ongoing pain in mice with tissue or nerve injury.Cortical nNOS neurons co-express the NK1 receptor and are depolarized by Substance P in multiple mammalian species.A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.
P2860
Q24288817-EA485A03-9553-4145-9FD4-210DB4D3F01AQ24622323-0C4FD9BF-EF01-496D-ABC4-D03B67296585Q24654992-A801C388-7F70-4F8D-8C11-99D9839CE477Q26785438-63F76CB2-226E-41EC-8F5C-4D9C4B9BDF14Q27011310-89C21CDB-EFCC-4E42-A031-3CA66ECF300AQ27014840-574F2080-A2CA-4CF3-AD18-1951F09B5B68Q27308025-232B8967-BCAB-477A-80BA-2B096FE1217EQ28262693-471908A0-8BAF-4B87-8E47-37AD9E75F14CQ28478055-CD710394-A406-48B3-84EC-C87151DBA45CQ28543670-0C33A495-21DA-4ADD-B7A8-AA731E69844AQ30249165-01A69FC0-9620-4186-855E-2E3709457FCAQ31036354-339BABE5-4754-4519-82E3-1C79F013345FQ33523625-72D64D90-C6BA-4888-A31F-BE0CEE2D3797Q33819256-33115B05-8BDE-4DF0-A5D1-F38F247F0A19Q33893991-B2572DD7-9955-41EB-A2F4-BB553592EB5CQ34096999-1CE5DC03-B235-4043-A589-5FA82EDFF444Q34190355-AF0FB6B5-E854-4B12-ABDF-FC738D988879Q34388992-A8AD2C70-E54D-44EA-A0B3-C5C9E1C0B460Q34409219-3922F868-D935-4A5B-8B0C-59FDA14721E3Q34413850-54B83811-2807-403C-98D3-FB287FE8C6E3Q34553942-66581C5E-9DC8-4CC7-8BDE-56C81FF21ECAQ34588695-4833730E-52CE-4EB8-B708-B8A8797D40F1Q34602588-14FDA9C8-7C66-4566-9F3F-D7A38E0C13F9Q34692273-EDA7604C-53B3-44DE-BBCC-762851F1613BQ35025200-1E0699D6-785A-4A76-A3A8-29FADE3519C6Q35047055-26728797-EDED-4280-9098-FCEFCC6FFCD8Q35058471-A14296A5-6812-42E9-87BE-6D3FB11E38C9Q35069775-A84C0209-807B-4184-AF28-D536DBF83961Q35110316-AC92DE12-53BF-460F-AAD7-4E644EC9C88FQ35203278-E8755841-95F0-4A8C-A7D8-3114F24A02BBQ35545240-8B20ECB0-0CB3-40F2-AD0E-F05905E9ECAAQ35589944-CDD5C9AD-1E22-4C27-88F6-1999B831C05EQ35673827-AD3D7668-7078-40CF-9FD1-F0D98D6FDB99Q35826364-4B95506A-A703-492F-AC98-6D11D2428DDEQ35904210-C968D9DD-4FD1-4C50-84A4-5C858D39E29AQ35935827-C37AD4D9-6806-41F2-B28D-B1E6B1E06368Q35946504-ECBCA4B5-F7DF-4AF5-B5C9-D16F91DB2A09Q36007686-F89F3818-32B8-4E09-AD0B-C67E97834802Q36009120-FA1B3679-9AE1-47E5-B6EF-CE19C121A727Q36011829-366F010B-0C9A-4AD9-8F62-2E3EC9C0F26C
P2860
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@ast
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@en
type
label
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@ast
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@en
prefLabel
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@ast
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@en
P1476
NK1 (substance P) receptor antagonists--why are they not analgesic in humans?
@en
P2093
P304
P356
10.1016/S0165-6147(00)01502-9
P577
2000-07-01T00:00:00Z